India CDMO Market to Hit USD 15.4 Billion by 2033 by 2033 | 7.7% CAGR | Get Free Sample Report

India CDMO Market Overview

The India CDMO market size reached USD 7.9 Billion in 2024 and is expected to grow to USD 15.4 Billion by 2033, exhibiting a CAGR of 7.7% during the forecast period of 2025-2033. This growth is driven by rising demand for contract manufacturing services in pharmaceuticals, especially complex generics, HPAPIs, and sterile injectables, supported by a strong regulatory framework and cost advantages. The market also benefits from expanding global footprints catering to major pharmaceutical markets such as the U.S. and Europe.

Update: "We are in the process of updating our reports to cover the 2026-2034 forecast period. For the most recent data, insights, and industry updates, please click on 'Request Free Sample Report'."

Request Free Sample Report: https://www.imarcgroup.com/india-cdmo-market/requestsample

India CDMO Market Study Assumption Years

• Base Year : 2024
• Historical Year/Period : 2019-2024

India CDMO Market Key Takeaways

• Current Market Size : USD 7.9 Billion
• CAGR : 7.7%
• Forecast Period : 2025-2033
• The market is propelled by increasing demand for contract development and manufacturing services in the pharmaceutical sector.
• Strong government incentives, including the Production Linked Incentive (PLI) scheme, enhance investment and market growth.
• Indian CDMOs are attracting global companies due to cost efficiency, skilled workforce, and robust regulatory frameworks.
• Expansion in biologics and biosimilars manufacturing capabilities is a significant growth driver.
• Advances in digital transformation and adoption of Industry 4.0 technologies improve operational efficiency in the market.

India CDMO Market Growth Factors

Factors such as the country's established contract development and manufacturing services infrastructure, a skilled talent pool, and government initiatives like the Production Linked Incentive (PLI) scheme supporting foreign and domestic pharmaceutical sector investment are expected to drive the growth of the India CDMO (contract development and manufacturing organization) market greatly. Facilitation of favorable regulations by the Indian government has also helped in this growth.

The increased demand for low-cost healthcare worldwide has mandated the need for pharmaceutical companies to rely on outsourcing their manufacturing needs to Indian contract development and manufacturing organizations because India is able to manufacture pharmaceuticals at lower costs without compromising on quality. India has since been a priority destination for contract development and manufacturing organization services. Growth of domestic research and development investments is also an increase.

Sustainability and green chemistry are important emerging priorities for pharmaceutical manufacturing, and Indian CDMOs have a growing opportunity to develop green manufacturing processes in this area. Planned alliances with global biotechnology companies and entry into emerging economies represent major opportunities for the growth of Indian contract development and manufacturing organizations (CDMOs) in the global pharmaceutical supply chain.

India CDMO Market Trends

The India CDMO market is witnessing numerous trends that will strengthen its growth in future, including an increase in biologics and biosimilars manufacturing owing to the outsourcing of complex biologic drug development and manufacturing services. Indian CDMOs are focusing on strengthening their biomanufacturing capabilities to include mammalian and microbial expression systems and regulatory compliance such as the USFDA and EMA.

With pharma and biopharma companies seeking full-service contract development and manufacturing organizations (CDMOs) for drug discovery and formulation development, clinical trial supply, commercial drug product manufacturing, and compliance with global regulatory requirements, Indian CDMOs are upgrading their facilities and capabilities with the use of AI for drug discovery, process automation and real-time data analytics.

Digital transformation driven by Industry 4.0 technologies such as manufacturing execution systems, predictive analytics, IoT enabled equipment monitoring and blockchain, as well as cloud collaborative platforms for project management and client communication, allows Indian CDMOs to differentiate themselves as technologically advanced and cost-competitive supply chain partners in the global market for pharmaceutical contract manufacturing.

Buy the Full Report for Complete Data, Trends, and Opportunities: https://www.imarcgroup.com/checkout?id=30719&method=1337

India CDMO Market Segmentation

Service Type Insights

• Contract Development Services: This segment includes preclinical development, clinical development, and analytical and bioanalytical services, providing comprehensive drug development support.
• Contract Manufacturing Services: Comprising active pharmaceutical ingredients (APIs) manufacturing, finished dosage forms (FDFs) manufacturing, biologics manufacturing, and packaging, this segment focuses on large-scale production activities.

Type Insights

• Small Molecules: Traditional chemical-based drug substances.
• Biologics: Complex drugs produced using biotechnological methods.
• Biosimilars: Biologically similar versions of biologic drugs.
• Vaccines: Pharmaceutical preparations for immunization.
• Others: Additional product types in the CDMO space.

Scale of Operation Insights

• Commercial Scale: Large-scale production targeting market supply.
• Clinical Scale: Smaller scale operations focused on clinical trial batches.
Therapeutic Area Insights
• Oncology: Treatments related to cancer.
• Cardiovascular Diseases: Medications targeting heart and blood vessel conditions.
• Infectious Diseases: Medicines for bacterial, viral, and other infections.
• Central Nervous System (CNS) Disorders: Drugs addressing neurological conditions.
• Others: Additional therapeutic areas covered by CDMOs.

Regional Insights

• North India
• South India
• East India
• West India

Summary: The dominant region is South India, which holds the largest market share driven by its advanced pharmaceutical infrastructure and investments. The entire India CDMO market is expected to grow at a CAGR of 7.7% during the forecast period.

India CDMO Market Key Players

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
India CDMO Market Recent Developments & News

In February 2025, Granules India acquired Swiss CDMO Senn Chemicals AG for CHF 20 Million (approx. INR 192.5 Crore), marking its entry into peptide therapeutics and enhancing its European market presence.

In December 2024, Akums Drugs and Pharmaceuticals partnered with a global pharma company to supply oral liquid formulations for the European market, under a Euro 200 million agreement effective from 2027, with regulatory approvals anticipated by 2026. These strategic moves support the expanding India CDMO market.

India CDMO Market Key Highlights of the Report

• Comprehensive quantitative analysis of India CDMO market segments and forecasts from 2019-2033.
• Detailed insights into market drivers, challenges, and opportunities.
• Porter's five forces analysis to assess industry competitiveness and attractiveness.
• Competitive landscape with key player positioning and strategic insights.
• Segment-wise market assessment by service type, type, scale of operation, and therapeutic area.
• Regional market analysis covering North, South, East, and West India.

Get Your Customized Market Report Instantly: https://www.imarcgroup.com/request?type=report&id=30719&flag=E

Customization Note: If you require any specific information not covered within this report's scope, we will provide it as part of the customization.

Explore More Research Reports & Get Your Free Sample Now:

India Insulin Market: https://www.imarcgroup.com/india-insulin-market/requestsample

India Active Pharmaceutical Ingredients Market: https://www.imarcgroup.com/india-active-pharmaceutical-ingredients-market/requestsample

India Orthopedic Devices Market: https://www.imarcgroup.com/india-orthopedic-devices-market/requestsample

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201971-6302

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

This release was published on openPR.